Clinical trials
Breast Cancer (Triple Negative Breast Cancer (TNBC)) clinical trials
Below are recruiting breast cancer (triple negative breast cancer (tnbc)) clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT07378306RecruitingPhase 2
Fasting-mimicking diet with chemo-immunotherapy for triple-negative breast cancer
This trial tests whether adding a special low-calorie diet (called a fasting-mimicking diet) to standard chemotherapy and immunotherapy can help treat triple-negative breast cancer before surgery. It aims to see if this combination makes the treatment work better.
Guangzhou, GuangdongAges 18–70 - NCT07290153Recruiting
Psychological health and immunotherapy for TNBC
This study looks at how psychological factors and the immune system affect treatment response in women with triple-negative breast cancer. Researchers will use questionnaires and biological samples to understand these links.
Shanghai, Please SelectAges 18–70 - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Scottsdale, ArizonaAges 18 years+ - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT07829848Recruiting
Skip extra radiation for breast cancer patients who respond well to treatment
This trial tests whether women and men with advanced, non-metastatic breast cancer can safely skip an extra radiation boost to the lymph nodes if their tumors respond well to pre-surgery chemotherapy or targeted therapy. The goal is to reduce side effects while keeping cancer control.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03815890RecruitingPhase 2
Pre-surgery nivolumab for certain types of breast cancer
This trial tests whether giving nivolumab before surgery (neoadjuvant treatment) can improve outcomes for people with certain resectable breast cancers. It focuses on tumor types linked to immune activity (like triple-negative and specific lab markers).
AmsterdamAges 18 years+ - NCT07359404Enrolling by invitationPhase 2
Sacituzumab Govitecan plus Bevacizumab for metastatic TNBC
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06165900RecruitingPhase 2
Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Shenyang, LiaoningAges 18–75 - NCT06704945RecruitingPhase 3
Skipping armpit surgery after good chemo response
This trial tests whether it's safe to skip armpit surgery in people whose breast cancer has responded well to chemotherapy and whose lymph nodes appear cancer-free on ultrasound. It aims to reduce side effects like arm swelling while still controlling the cancer.
SeoulAges 19 years+ - NCT06097156Recruiting
Automated blood test for breast cancer monitoring
This trial tests an automated device that prepares blood samples to detect cancer-related changes. It aims to improve how doctors monitor breast cancer that has spread, without needing a tissue biopsy every time.
MilanAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer (triple negative breast cancer (tnbc))?
- Yes. Clin2 currently lists 254 recruiting breast cancer (triple negative breast cancer (tnbc)) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer (triple negative breast cancer (tnbc)) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer (triple negative breast cancer (tnbc)) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.